Indication: Hematological Malignancies
Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage
Line of Therapy: 2nd or 3rd
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Delta-Fly Pharma, Inc.
Email for more information: Heme-NCIResearch@nortonhealthcare.org